Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

Recruiting now · Phase 4

Conditions studied: Subarachnoid Hemorrhage, Aneurysmal

In brief

The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old. Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.

Key facts

Study ID

NCT06119061

Run by

Aaron Cook

People needed

20

Starts

2024-07-02

Expected to finish

2026-12-01

Last updated by the study team

2025-12-26

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult aged 18-85 years
• Actively draining ventriculostomy

You may not qualify if…

• history of hypersensitivity to telavancin or similar agents
• reduced renal function (estimated creatinine clearance < 50/ml) at the time of consent
• severe anemia (hemoglobin < 7gm/dl)
• vulnerable population (pregnant, prisoner)
• concomitant antimicrobial therapy

Where it is running

• University of Kentucky — Lexington, Kentucky, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.